Newskin Whole Embryonic Layer Anti-aging Skin Renewal Powde Powder
NDC Package 87130-002-01
Package Information
Newskin Whole Embryonic Layer Anti-aging Skin Renewal Powde (maritime pine, schisandra chinensis seed, centella asiatica triterpenoids) powders is ages 18-39: 6g every 12 hours; not more than 12g in 24hoursAges 40-65: 6g every 8 hours; not more than 18g in 24hours. This formulation utilizes a powder delivery system. Marketed by Japan Medical Biotechnology Limited, this product is identified by NDC 87130-002.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 87130 - Japan Medical Biotechnology Limited
- 87130-002 - Newskin Whole Embryonic Layer Anti-aging Skin Renewal Powde
- 87130-002-01 - 10 BOTTLE in 1 BOX / 6 g in 1 BOTTLE
- 87130-002 - Newskin Whole Embryonic Layer Anti-aging Skin Renewal Powde
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (87130-002). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 87130-002-01 identifies a specific commercial package of 10 bottle in 1 box / 6 g in 1 bottle of Newskin Whole Embryonic Layer Anti-aging Skin Renewal Powde, a human over the counter drug labeled by Japan Medical Biotechnology Limited. This powder is formulated for oral use and contains centella asiatica triterpenoids; maritime pine; schisandra chinensis seed as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Japan Medical Biotechnology Limited on October 20, 2025. The current certification is valid through December 31, 2027.
How is this Japan Medical Biotechnology Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 87130000201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.